Cargando…
Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression
High expectations have been set on gene therapy with an AAV-delivered shortened version of dystrophin (µDys) for Duchenne muscular dystrophy (DMD), with several drug candidates currently undergoing clinical trials. Safety concerns with this therapeutic approach include the immune response to introdu...
Autores principales: | Starikova, Anna V., Skopenkova, Victoria V., Polikarpova, Anna V., Reshetov, Denis A., Vassilieva, Svetlana G., Velyaev, Oleg A., Shmidt, Anna A., Savchenko, Irina M., Soldatov, Vladislav O., Egorova, Tatiana V., Bardina, Maryana V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764061/ https://www.ncbi.nlm.nih.gov/pubmed/35039573 http://dx.doi.org/10.1038/s41598-022-04892-x |
Ejemplares similares
-
CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein
por: Egorova, Tatiana V., et al.
Publicado: (2023) -
CRISPR/Cas9-generated mouse model with humanizing single-base substitution in the Gnao1 for safety studies of RNA therapeutics
por: Polikarpova, Anna V., et al.
Publicado: (2023) -
In-Frame Deletion of Dystrophin Exons 8–50 Results in DMD Phenotype
por: Egorova, Tatiana V., et al.
Publicado: (2023) -
Muscle-Specific Promoters for Gene Therapy
por: Skopenkova, V. V., et al.
Publicado: (2021) -
CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene
por: Egorova, Tatiana V., et al.
Publicado: (2019)